Compare CCC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | EWTX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | 2185 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | N/A | 2021 |
| Metric | CCC | EWTX |
|---|---|---|
| Price | $4.95 | $33.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.44 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 9.2M | 739.7K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $11.50 |
| 52 Week High | $8.68 | $34.00 |
| Indicator | CCC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 58.59 |
| Support Level | $4.81 | $28.72 |
| Resistance Level | $6.40 | N/A |
| Average True Range (ATR) | 0.29 | 1.48 |
| MACD | -0.09 | 0.15 |
| Stochastic Oscillator | 3.50 | 76.47 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.